Contract research provider Icon on Wednesday said it will buy PRA Health Sciences for about $12 billion in cash and stock, snapping up one of the larger independent companies in the drugmaker services business.
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, and government and public health organisations, today announced it has entered into a definitive agreement to acquire PRA Health Sciences, Inc. (NASDAQ: PRAH) in a cash and stock transaction valued at approximately $12 billion, with the per share merger consideration consisting of $80 in cash and 0.4125 shares of ICON stock. The consideration represents an approximately 30% premium to PRA’s closing price as of February 23rd, 2021.
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government and public health organisations, today announced it has been awarded Best Clinical Research Organisation (CRO) at the Vaccine Industry Excellence (ViE) Awards. ICON was presented with the award at the World Vaccine Congress which took place virtually last week.
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government and public health organisations, today announced it has been awarded Best Clinical Research Organisation (CRO) at the Vaccine Industry Excellence (ViE) Awards. ICON was presented with the award at the World Vaccine Congress which took place virtually last week.
ICON plc, (NASDAQ: ICLR)Â a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government and public health organisations, today announced that it is launching Accellacare a global clinical research network offering patients easier and faster access to innovative treatments and offering customers the option to deploy decentralised trials. The site network includes previously acquired PMG Research in the US and MeDiNova Research in EMEA.
Contract research organization Icon has poached Kristen Buck, M.D., from healthcare data and analytics firm Optum (part of the UnitedHealth Group) as its new chief medical officer.
Veeva Systems explains reason for moving deeper into services through the acquisition of Physicians World.
Acquisitive Icon is at it again as it snaps up a majority stake in British site network company MeDiNova Research with an option to buy out the remaining shares penned into the deal.